Cassava Sciences (SAVA)
(Delayed Data from NSDQ)
$28.71 USD
+0.20 (0.70%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $28.60 -0.11 (-0.38%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth D Momentum F VGM
Brokerage Reports
Cassava Sciences, Inc. [SAVA]
Reports for Purchase
Showing records 81 - 100 ( 132 total )
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Cassava Slowly Continues to Enroll Patients, Open-Label Improvements Down: $8 Price Target
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 81122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Slow Enrollment Continues, Open-Label Interim Data Does Not Look Promising
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
A Gem Emerges in 12-Month Open-Label Study Data; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 8122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Possible DOJ Investigation into SAVA?s Roots: Maintain SELL: $8 Price Target
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 72122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 71122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 7122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 62122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 61122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Another of Cassava?s Roots Has Been Pulled: Maintain SELL: $8 Price Target
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for SAVA 6122
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Comprehensive Technical and Fundamental Analysis for SAVA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Phase 3 Enrollment Lagging; At Current Pace Could Take ~8 Years: Maintain Sell, $8 PT
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Momentum Regained With Uptick in Phase 3 Enrollment; Reiterate Buy and $124 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
SavaDx: Antibody or No Antibody, Unclear; Maintain SELL, $8 Price Target
Provider: Univest Securities, LLC
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Comprehensive Technical and Fundamental Analysis for SAVA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Comprehensive Technical and Fundamental Analysis for SAVA.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cassava Sciences, Inc.
Industry: Medical - Drugs
Cassava?s Roots are Being Investigated: Maintain SELL, $8 Price Target
Provider: Univest Securities, LLC
Analyst: Research Department